JPMorgan Starts Luminex (LMNX) at Neutral
More News related to LMNX
- Luminex Corporation Announces Executive Appointments
- Luminex Corporation Announces Full Commercial Launch of the High-Throughput FLEXMAP 3D(TM) Multiplexing System
- Luminex Launches Two New Cystic Fibrosis Tests in Europe
- Luminex Expands Globally and Opens Facility in People's Republic of China
- Northland Securities Initiates Coverage on Luminex (LMNX) with an Outperform
More News related to New Coverage
- Stifel Nicolaus Starts Horsehead Holding (ZINC) at Buy
- Bank of America Resumes Coverage on Bristol-Myers (BMY) with a Neutral
- Credit Suisse Resumes Coverage on Rio Tinto (RTP) with an Outperform
JPMorgan initiates coverage on Luminex Corporation (Nasdaq: LMNX) with a Neutral rating.
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for applications in the life sciences industry.
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
